ASMS 2026: Solving Proteomics’ Next Bottleneck
At the 74th American Society for Mass Spectrometry (ASMS) Conference in San Diego, the obvious story was hardware. Vendors showcased faster acquisition, higher sensitivity, alternative fragmentation, spatial workflows, and software ecosystems. New or highlighted...
Peptistar Began Operation of the Asahi Kasei FO-MD System at Manufacturing Scale
Japanese CDMO Peptistar reports that it has integrated Asahi Kasei’s forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs).
Asahi Kasei announced in 2018 the development of a...
In Huntington’s Mouse, Optogenetic Activation of VIP Neurons Restores Brain Function
Huntington’s disease is a devastating brain disorder in which damage to nerve cells leads to progressively worsening cognitive and movement abilities. While the genetic mutation responsible for the condition is well known, the details...
Cytiva Completes Doubling of Utah Site’s Liquid Media Production Capacity
Cytiva has completed an expansion of its Logan, UT, facility that effectively doubles its liquid media production capacity, a project designed to support supply chain continuity for customers relying on the company for their...
Genome Editing at the Turning Point—Bringing CRISPR to Clinical Reality
Register Now
Laura Sepp-Lorenzino, PhD Former CSOIntellia Therapeutics View Bio
Panelist ...
Recoded E. coli Promises More Scalable Weight Loss Drug Production
The manufacturing of weight loss drugs at large scale could get cheaper and more sustainable thanks to an engineered strain of Escherichia coli (E. coli) bacteria.
The fully recoded E. coli, designed to use only...
Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering
VectorBuilder and MaxCyte formed a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder’s MiniVec plasmid system and MaxCyte’s clinical electroporation platform for ex vivo cell engineering.
Officials at both companies say...
Nextgen Platform Combines VectorBuilder and Maxcyte Technologies to Boost Clinical-Grade Cell Engineering
VectorBuilder and MaxCyte formed a strategic partnership focused on co-developing a new gene delivery solution using VectorBuilder’s MiniVec plasmid system and MaxCyte’s clinical electroporation platform for ex vivo cell engineering.
Officials at both companies say...
China Sets Framework for Advanced Therapeutic Development
China’s Order 818—Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies—establishes a new commercialization pathway for cell and gene therapeutics, gene editing, and other advanced therapeutics. More...
Perseverance, Persistence Key to CAR T Success, Say Ross Prize Winners Carl June and...
NEW YORK CITY — Patients, colleagues and peers gathered in midtown Manhattan last week to celebrate Carl June, MD, and Michel Sadelain, MD, PhD, who shared the 13th annual Ross Prize in Molecular Medicine.
The...
